STAT+: Cytokinetics Drug Myqorzo Meets Twin Efficacy Goals in Study of Genetic Heart Disease

Why It Matters

Broadening Myqorzo to non‑obstructive HCM could double the addressable patient pool and generate multi‑billion‑dollar revenue, reshaping the HCM treatment landscape.

Key Takeaways

• ACACIA trial met both primary efficacy endpoints with statistical significance.
• Myqorzo improved symptoms and cardiovascular fitness in non‑obstructive HCM.
• Expanded indication could raise peak sales to $5 billion annually.
• Success may accelerate FDA review and broader market adoption.
• Cytokinetics moves from niche to mainstream HCM therapy.

Pulse Analysis

Hypertrophic cardiomyopathy (HCM) affects roughly one in 500 people, with the obstructive form traditionally receiving the most therapeutic attention. Non‑obstructive HCM, while less dramatic in outflow obstruction, still causes debilitating symptoms, reduced exercise capacity, and heightened risk of heart failure. Until now, treatment options have been limited to beta‑blockers, calcium‑channel blockers, and lifestyle modifications, none of which address the underlying molecular dysfunction. Cytokinetics entered the market in 2024 with Myqorzo, a myosin inhibitor approved for obstructive HCM, offering a disease‑modifying mechanism that directly improves cardiac contractility.

The Phase 3 ACACIA study enrolled 450 patients with genetically confirmed non‑obstructive HCM and evaluated Myqorzo against placebo over 24 weeks. The trial achieved its dual primary endpoints: a statistically significant reduction in New York Heart Association functional class and a measurable increase in peak oxygen consumption (VO₂ max). These outcomes demonstrate that Myqorzo not only alleviates symptoms but also enhances cardiovascular fitness, a rare achievement for HCM therapies. The robust data set positions the drug for a supplemental indication filing, potentially streamlining the FDA’s review process. S.

to over 70,000 total HCM cases, effectively more than doubling its sales horizon. Analyst forecasts now peg peak annual revenue at $5 billion, reflecting both higher patient numbers and premium pricing justified by the drug’s unique mechanism. The broader label would also pressure competitors—such as mavacamten’s developer—to accelerate their own pipeline programs. For Cytokinetics, the success marks a transition from a niche launch to a cornerstone cardiovascular franchise.